Silvia Vázquez-Cuesta1,2,3*
Nuria Lozano García1,2
Ana I. Fernández2,4María Olmedo1,2Martha Kestler1,2,5
Luis Alcalá1,2,6Mercedes Marín1,2,5,6
Javier Bermejo2,4,5,7Francisco Fernández-Avilés Díaz2,4,5,7Patricia Muñoz1,2,5,6Emilio Bouza1,2,5,6Elena Reigadas1,2,5 on behalf of HGUGM Microbiome Group- 1Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- 2Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
- 3Biochemistry and Molecular Biology Department, Faculty of Biology, Universidad Complutense de Madrid (UCM), Madrid, Spain
- 4Department of Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- 5Medicine Department, School of Medicine, Universidad Complutense de Madrid (UCM), Madrid, Spain
- 6Centro de Investigación Biomédica en red de Enfermedades Respiratorias (CIBERES CB06/06/0058), Madrid, Spain
- 7Centro de Investigación Biomédica en red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
Introduction: Clostridioides difficile infection (CDI) is the main cause of nosocomial diarrhoea in developed countries. Recurrent CDI (R-CDI), which affects 20%-30% of patients and significantly increases hospital stay and associated costs, is a key challenge. The main objective of this study was to explore the role of the microbiome and calprotectin levels as predictive biomarkers of R-CDI.
Methods: We prospectively (2019-2021) included patients with a primary episode of CDI. Clinical data and faecal samples were collected. The microbiome was analysed by sequencing the hypervariable V4 region of the 16S rRNA gene on an Illumina Miseq platform.
Results: We enrolled 200 patients with primary CDI, of whom 54 developed R-CDI and 146 did not. We analysed 200 primary samples and found that Fusobacterium increased in abundance, while Collinsella, Senegalimassilia, Prevotella and Ruminococcus decreased in patients with recurrent versus non-recurrent disease. Elevated calprotectin levels correlated significantly with R-CDI (p=0.01). We built a risk index for R-CDI, including as prognostic factors age, sex, immunosuppression, toxin B amplification cycle, creatinine levels and faecal calprotectin levels (overall accuracy of 79%).
Discussion: Calprotectin levels and abundance of microbial genera such as Fusobacterium and Prevotella in primary episodes could be useful as early markers of R-CDI. We propose a readily available model for prediction of R-CDI that can be applied at the initial CDI episode. The use of this tool could help to better tailor treatments according to the risk of R-CDI.
1 Introduction
The clinical severity of Clostridioides difficile infection ranges from asymptomatic, mild, moderate and severe episodes and pseudomembranous colitis to toxic megacolon, sepsis or death (Rupnik et al., 2009).
One of the current challenges associated with CDI is recurrent CDI (R-CDI), which usually affects 20%-30% of patients with a first CDI infection and increases to 40%-65% after a first R-CDI episode (Barbut et al., 2000; Leffler and Lamont, 2015; Larrainzar-Coghen et al., 2016; Smits et al., 2016).
The costs associated with R-CDI in the United States reach $94,209 per year for patients with 1 R-CDI episode, increasing to $207,733 per year for patients with 3 or more R-CDI, with a length of stay ranging from 8.3 to 17.9 days (Feuerstadt et al., 2020). In Europe each episode of R-CDI involves an average cost of €40,941 and a length of stay of 55 days; these costs are 4-fold higher and with a 2.5-fold longer stay than for a primary CDI episode (Wingen-Heimann et al., 2022).
The main risk factors associated with R-CDI include advanced age, hospital exposure, treatment with proton pump inhibitors, prior antibiotic treatment and initial disease severity (Eyre et al., 2012; Lupse et al., 2013; Alrahmany et al., 2021).
The imbalance of gut’s microbial community, known as gut microbiota dysbiosis, is strongly linked to the risk of CDI, especially that resulting from the action of antibiotics (Buffie et al., 2012; Theriot et al., 2016). However, very few papers in the literature investigate the association between gut microbiota factors and the risk of R-CDI, and those that do include a low number of patients and report very disparate results (Khanna et al., 2016; Seekatz et al., 2016; Pakpour et al., 2017; Dawkins et al., 2022).Khanna et al. included 88 patients with CDI, 22 of them developed R-CDI; Seekatz et al. included 93 patients with CDI and 32 developed R-CDI, and Dawkins et al. included 53 patients with CDI and 19 developed R-CDI, all they found no significant differences in either alpha diversity or beta diversity. Pakpour et al. included 31 patients with CDI, of them 11 developed R-CDI, they found significant differences in alpha diversity and beta diversity. Because of the close relationship between gut microbiota and C. difficile, treatment with faecal microbiota transplantation for R-CDI to restore patients’ gut microbiota and prevent future recurrences is already included in IDSA/SHEA guidelines (McDonald et al., 2018). For this reason, clinical trials are now investigating the use of faecal microbiota transplantation in first episodes to reduce the risk of recurrence (Kates et al., 2020).
New CDI treatments for reducing recurrences include fidaxomicin, bezlotoxumab, and SER-109 (Escudero-Sánchez et al., 2020; Dubberke et al., 2022; Feuerstadt et al., 2022; Johnson et al., 2022; Tashiro et al., 2022).Both fidaxomicin and bezlotoxumab involve reducing damage to the gut microbiota in CDI patients, which has been shown to result in lower recurrence rates. SER-109 is an orally administered faecal microbiota treatment, helping microbiota recovery to prevent possible recurrences, just like the faecal microbiota transplants that have been performed for years. However, new CDI treatments are costly, and recent European guidelines suggest applying a risk stratification strategy in cases of economic restraints (van Prehn et al., 2021). Many attempts have been made to try to identify or profile patients at high risk for CDI (van Rossen et al., 2022), to date, no reliable objective markers to help predict who is at increased risk of R-CDI have been identified.
There are different markers of inflammation that can be measured directly in faeces, including faecal leukocyte analysis, in which blood is drawn from the patient, the leukocytes are labelled with a radioisotope and reintroduced to the patient. Stool samples are then collected and quantified for labelled leukocytes (Stathaki et al., 2009). Its main drawback is that it is invasive and exposes patients to radiation. Other methods involve measuring leukocyte proteins such as myeloperoxidase, lysozyme, elastase, S100A12, lactoferrin and calprotectin in the stool (Gonzalez et al., 2015; Lehmann et al., 2015; Galgut et al., 2018). Of these, calprotectin has been shown to be the most stable in faeces (Gonzalez et al., 2015) and is therefore the most commonly used in clinical practice, hence we included faecal calprotectin in our analyses.
Calprotectin is a protein secreted mainly by neutrophils, but also by macrophages, monocytes and dendritic cells (Odink et al., 1987; Edgeworth et al., 1991; Kumar et al., 2003). It is known to be a good marker of intestinal inflammation, can be obtained non-invasively and is stable at room temperature (Xu and Geczy, 2000; Lasson et al., 2015).Several studies have examined the role of calprotectin as a marker of severity of CDI with calprotectin levels being higher the more severe the CDI episode (Peretz et al., 2016; Kim et al., 2017; Suarez-Carantoña et al., 2021) and as a marker of CDI itself with higher levels of calprotectin in patients with CDI than in patients without CDI (Popiel et al., 2015; Barbut et al., 2017).
The high associated health and economic burden of R-CDI calls for the development of novel strategies by which R-CDI can be prevented in susceptible patients (Heimann et al., 2018; Reigadas Ramirez and Bouza, 2018). Profiling differences between gut microbiota and calprotectin levels in patients with CDI could help to predict which patients are more likely to experience R-CDI.
The main objective of this study was to explore the role of the microbiome and calprotectin as predictive biomarkers of R-CDI.
2 Methods
2.1 Setting, design, and study population
This study was carried out at Hospital General Universitario Gregorio Marañón in Madrid (Spain), a tertiary university hospital with 1,350 beds. Toxigenic C. difficile is routinely investigated in all diarrhoeic stool samples from patients older than 2 years. The microbiology laboratory receives samples both from the hospital itself and from 13 outpatient centres in the same area.
We conducted a prospective study from January 2019 to April 2021. We enrolled patients over 2 years old with a positive test result for toxigenic C. difficile and met the clinical criteria for CDI. We excluded patients younger than 2 years old because they have a high colonisation rate, which in many cases makes it difficult to determine the true cause of diarrhoea, in infants less than 7 days are 15%, in infants between 6 and 12 months 41% and 22% in 2 year old (Tougas et al., 2021). It appears that the infants’ gut is immune to the effects of toxins A and B although the mechanism is unknown, very few cases of CDI have been described in infants under 2 years of age (Jangi and Lamont, 2010). We collected clinical data and faecal samples from all patients. Patients were classified into 2 groups: patients with a primary CDI episode who did not subsequently develop recurrent CDI (non-recurrent) and patients with a primary CDI episode who subsequently developed recurrent CDI (recurrent).
2.2 Definitions
An episode of CDI was defined as the presence of a positive toxigenic CDI test result, together with diarrhoea (≥3 unformed stools in 24 h) or findings of pseudomembranous colitis by colonoscopy, following the definitions set out in the guidelines of the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) (McDonald et al., 2018).
CDI is considered recurrent when it recurs within 8 weeks after a previous episode, provided the symptoms from the previous episode resolved after completion of the initial treatment (van Prehn et al., 2021). Having new symptoms and a positive sample after 60 days was considered a new episode.
Defined daily dose (DDD) is defined in the “WHO Collaborating Centre for Drug Statistics Methodology” as the assumed average maintenance dose per day in the case of a drug used for its main indication in adults (WHO, 2021).
We classified antimicrobial drugs as anaerobic, as previously described by Mulder et al, “We also classified the antimicrobial drugs in antimicrobial drugs with anaerobic activity (consisting of combinations of penicillins, including beta-lactamase inhibitors (J01CR), lincosamides (J01 FF) and imidazole derivatives (metronidazole) (J01XD): anaerobic+)…” (Mulder et al., 2020).
The severity of the CDI episode was defined according to the SHEA and IDSA guidelines (McDonald et al., 2018).
Death was considered CDI-related when there were no other attributable causes and/or it occurred within 10 days after the diagnosis of CDI and/or was due to known complications of CDI.
As for microbiome-related definitions, we considered richness as the number of different species found in a sample (Whittaker et al., 2001). Evenness (Pielou index) was defined as the degree to which different species are similar or uniform in abundance. Diversity indicated the degree of species richness and abundance, where alpha diversity is referred to the diversity within an individual -Inverse Simpson index: an indication of the richness in a community with the same evenness; and Shannon index: takes into account the number of species living in a habitat (richness) and their relative abundance (evenness)- and beta diversity referred to the difference in diversity between individuals (Whittaker et al., 2001).
We considered as microbiota-related diseases the following: cholelithiasis, colorectal cancer, hepatic encephalopathy, idiopathic constipation, inflammatory bowel disease, irritable bowel syndrome, familial Mediterranean fever, gastric lymphoma or carcinoma, arthritis, asthma, atopy, dermatitis, psoriasis, autoimmune disease, fatigue syndrome, diabetes mellitus, hypercholesterolaemia, idiopathic thrombocytopenic purpura, myocardial ischaemia, metabolic syndrome, behavioural disorders, multiple sclerosis, myoclonus dystonia, non-alcoholic fatty liver disease, oxalate kidney stones and Parkinson’s disease.
2.3 Detection of toxigenic C. difficile
Samples were processed using a rapid detection kit for toxigenic C. difficile. This rapid test consists of glutamate dehydrogenase antigen and toxins A and B detection by immunochromatography (C Diff Quik-Chek Complete assay, TechLab, Blacksburg, VA, USA) (Sensitivity 90.5%, specificity 93.1%, predictive positive value 76.4%, predictive negative value 97.6% in comparison with bacterial culture) and a real-time polymerase chain reaction (PCR) assay of the C. difficile toxin B gene (Xpert.C. difficile Assay, GeneXpert, Cepheid, Sunnyvale, CA, USA) (Sensitivity 98.79%, specificity 90.82%, predictive positive value 56.58%, predictive negative value 99.83% in comparison with bacterial culture).
In addition, all samples were cultured on C. difficile selective agar (bioMeriéux, Marcy l’Etoile, France). Suspected toxigenic C. difficile colonies were confirmed using immunochromatography (C Diff Quik-Chek Complete assay, TechLab, Blacksburg, VA, USA).
2.4 Calprotectin assay
Calprotectin levels were measured using EDITM Quantitative Faecal Calprotectin ELISA (Measurement range: 1 – 2000 µg/g stool) (Epitope Diagnostics, Inc, San Diego, CA, USA), according to the manufacturers’ instructions.
2.5 Clinical data
The demographic data collected included age and sex. Regarding clinical data, the underlying conditions were recorded using the McCabe and Jackson score for prognosis of underlying diseases. The McCabe score was used to categorise the risk of death by underlying comorbidities. The 3 categories were rapidly fatal (within 1 year), ultimately fatal (within 5 years) and non-fatal (>5 years) (Jackson and McCabe, 1962); comorbidity was graded according to the Charlson comorbidity index (Charlson et al., 1987). The Charlson comorbidity index is one of the most extensively used comorbidity indices (Huang et al., 2014). This index consists of 19 conditions, each of which is assigned a weighting of 1, 2, 3 or 6 based on the adjusted hazard ratio for each comorbidity. The sum of the weighted scores gives the total score (Yurkovich et al., 2015).
Other clinical data collected included antibiotic treatment, proton pump inhibitor use, nasogastric tube use, mechanical ventilation, surgery and chemotherapy or radiotherapy in the month prior to diagnosis of CDI. Regarding antibiotic consumption, the DDDs for each antibiotic were recorded. For the CDI episode, data on severity of the episode, treatment received, treatment failure, recurrence, mortality and CDI-related mortality were recorded.
2.6 Sample processing
Immediately upon receipt, the faecal samples were homogenized, aliquoted and stored at −80°C until the day of analysis. Total DNA was extracted from faecal samples using the Qiagen Fast QiaAmp DNA stool mini kit (QIAGEN, Valencia, CA, USA) according to the manufacturer’s protocol with the inclusion of a physical lysis step. The sample was lysed twice at 6.5m/s for 45 seconds in FastPrep-24 (MPBio, Derby, UK) with lysis matrix tubes E (MPBio, Derby, UK). The hypervariable V4 region of the 16S rRNA gene was amplified by PCR, with 515-806 primers (515:GTGCCAGCMGCCGCGGTAA, 806:GGACTACHVGGGTWTCTAAT) tailed with sequences to incorporate Illumina flow cell adapters and indexing barcodes (Illumina, San Diego, CA, USA). PCR amplification program was 1 cycle of 98°C 30 seconds; 25 cycles of 98°C 10 seconds, 60°C 20 seconds, 72°C 20 seconds; 1 cycle of 72°C 2 minutes. Q5® High-Fidelity 2X Master Mix (New England Biolabs, Ipswich, MA, USA)
Primer dimers and low-molecular-weight products were removed using Agencourt Ampure Beads (Beckman Coulter, Spain). Samples were quantified and quality was checked for amplicon size using the 4200 TapeStation (Agilent Technologies, Santa Clara, CA, USA). Amplicons were equimolar pooled and sequenced (2 × 250) on an Illumina Miseq platform (Illumina, San Diego, CA, USA) according to standard protocols.
2.7 Data analysis
The raw data were pre-processed, grouped by operational taxonomic units (OTUs) with 97% similarity and taxonomically classified using MOTHUR software (Patrick D. Schloss, PhD, © 2019, Michigan, USA) and SILVA and RDP databases. Analyses of species richness (OTUs observed), evenness (Pielou index), alpha diversity (Shannon index) and beta diversity (Bray-Curtys distance, unweighted unifrac distance) were performed with MOTHUR and R software (R Core Team, 2021, Vienna, Austria).
The statistical analyses were performed using R (R Core Team, 2021, Vienna, Austria). Frequencies were calculated for qualitative variables, and proportions were calculated with their 95% confidence interval (CI) following a binomial distribution. For quantitative variables, the median and interquartile range (IQR) or mean and standard deviation (SD) were calculated. Microbiota analyses were performed with R using the packages phyloseq, microbiome, microbiomeStat, vegan, DESeq2 and microeco.
The MaAslin2 (Multivariate microbial Association by Linear models) library was used to study the relationship between microbiota and clinical variables (Mallick et al., 2021). Differences between groups were determined using the χ2 test. Continuous variables were compared using the t test or the Mann-Whitney test (when a normal distribution could not be assumed). The normality of the distribution of continuous variables was assessed using the Kolmogorov-Smirnov test with the Lilliefors correction. A multivariate logistic regression model was used to assess predictors of R-CDI. The odds ratio (OR) and 95% CI were calculated. A p value <0.05 was considered significant. All significant variables in the bivariate study were included in the multivariate model, in the multivariate study a logistic regression was performed in which the weight of each variable was scored according to its odds ratio.
2.8 Ethical issues
This study was approved by the Ethics Committee of Hospital General Universitario Gregorio Marañón in Madrid (number MICRO.HGUGM.2016-029).
Participants’ informed consent was obtained before enrolment. All patients included in the study were given the sufficient time to make the decision to participate and understood each of the components of the study. Patients were also informed about their rights of access, rectification, cancellation and opposition.
2.9 Data availability
The data for this study have been deposited in the European Nucleotide Archive (ENA) at EMBL-EBI under accession number PRJEB57947 (https://www.ebi.ac.uk/ena/browser/view/PRJEB57947).
3 Results
During the study period, there were 1308 samples positive for toxigenic C. difficile from 906 patients. We obtained informed consent and a valid sample from 227 patients who had their first episode of CDI. Of these, 24 patients died before the end of the 2-month recurrence period follow-up, and 3 patients were lost to follow-up. We selected for analysis only samples from the patient’s first episode. Finally, we had 200 primary samples belonging to 200 patients, of whom 54 developed R-CDI and 146 did not.
3.1 Demographic and clinical characteristics
The median age of the patients was 67 years for those with non-recurrent disease and 78.50 years for those with recurrent disease. In both groups, there were more females than males (non-recurrent 54.8% [80/146]; recurrent 74.1% [40/54]; p = 0.013).
The most common underlying diseases were cardiovascular, metabolic, endocrine, nephrourological and gastrointestinal diseases (Table 1). The median Charlson comorbidity index was 4 (IQR: 2-6) in the non-recurrent group and 3.50 (IQR: 3-6) in the recurrent group (p= 0.256). Both groups contained a high percentage of patients with underlying diseases related to alterations of the microbiota, although this difference was not statistically significant (non-recurrent 65.8% [96/146]; recurrent 75.9% [41/54]; (p=0.169). Within this group of diseases, diabetes mellitus and ischemic heart disease were the most common (Table 1). Approximately 36% of all patients were immunocompromised (Table 1). Surprisingly, a higher percentage of patients had inflammatory bowel disease in the non-recurrent group (13.5%) than in the recurrent group (2.4%), and a higher percentage of patients had arthritis in the recurrent group (12.2%) than in the non-recurrent group (3.1%) (all p <0.05).
Table 1 Clinical characteristics of patients with a primary Clostridioides difficile infection episode.
No significant differences regarding risk factors for CDI were recorded in either of the groups. The main risk factor for developing CDI was antibiotic therapy in the month prior to sampling. In the patients with non-recurrent disease, the most frequent antibiotics were cephalosporins, followed by penicillins, carbapenems and quinolones, while in the patients with recurrent disease the most frequently administered antibiotics were cephalosporins, followed by quinolones, penicillins and carbapenems (Table 2). As for other CDI risk factors, treatment with proton pump inhibitors and being hospitalised were widely present (Table 3).
Table 2 Antibiotic treatment received 1 month prior to the primary Clostridioides difficile infection episode.
Table 3 Risk factors for Clostridioides difficile infection.
Regarding the severity of the CDI episodes, most were mild (non-recurrent 65.8%; recurrent 64.8%; p=0.901). There were 2 cases of toxic megacolon and 2 cases of pseudomembranous colitis, all in the non-recurrent group. Most CDI episodes (non-recurrent 57.5%; recurrent 38.9%; p=0.020) were hospital onset, healthcare facility–associated (Table 4). The median toxin B PCR cycle was lower in patients with recurrent disease than in those with non-recurrent disease (23.25 vs 26.10; p=0.003). Those with recurrent disease had higher levels of creatinine and faecal calprotectin than those with non-recurrent disease (all p<0.05) (Table 4).
Table 4 Characteristics of the primary Clostridioides difficile infection episode.
In both groups, most patients received treatment for CDI (non-recurrent, 97.9% [142/146]; recurrent, 100% [54/54]), mainly with vancomycin (non-recurrent, 85.6%, recurrent, 88.7%), followed by metronidazole (non-recurrent, 34.2%, recurrent, 26.4%). Fourteen patients included in this study had been enrolled in a clinical trial with faecal microbiota transplantation as their initial treatment. Few patients received fidaxomicin, and few patients received bezlotoxumab. There were no significant differences between the groups with respect to the CDI treatment they received (Table 4).
One patient with recurrent disease died (probably CDI-related), and no patients in the non-recurrent group died from a probably CDI-related condition. Both 30-day mortality and 90-day mortality (3.7% and 11.1%, respectively) were higher in the recurrent group than in the non-recurrent group (0% and 1.4% respectively) (all p<0.05) (Table 5).
Table 5 Outcome of the primary CDI episode.
3.2 Calprotectin levels and recurrent CDI predictive models
We analyzed 179 samples for calprotectin levels (128 from non-recurrent patients and 51 from recurrent patients). The median values obtained were 98.92µg/mg (IQR 8.33-191.05). We observed significant differences between non-recurrent and recurrent patients (92.91 µg/mg vs 150.36 µg/mg; p=0.01).We obtained a median calprotectin value of 81.32 µg/mg (IQR: 0.00-171.02) for mild CDI episodes and 148.16 µg/mg (IQR: 55.83-230.38) for severe CDI episodes (p=0.002).
We classified faecal calprotectin levels as >185µg/mg and <185µg/mg (45.1% and 21.1% of the recurrent group, respectively; p=0.01) (Table 6). Patients with faecal calprotectin >185µg/mg had a lower median toxin B PCR cycle threshold than patients with faecal calprotectin levels <185µg/mg (24.00 vs 25.60; p=0.034). Patients with faecal calprotectin higher than 185µg/mg had higher levels of leucocytes and more days of diarrhoea than patients with lower levels of faecal calprotectin. In addition, more patients had severe and severe-complicated CDI episodes with a calprotectin level >185µg/mg and more mild episodes with calprotectin <185µg/mg (all p<0.05) (Table 6).
Table 6 Characteristics of patients and Clostridioides difficile infection episode according to faecal calprotectin levels.
We ran a multivariate model and found the following independent risk factors for developing R-CDI: age, faecal calprotectin level >185µg/mg, toxin B PCR cycle threshold <23, immunosuppression, female sex, and creatinine levels higher than 1mg/dL (all p<0.05). We built a risk index for developing R-CDI based on the risk factors we obtained in the multivariable model (Table 7). The ROC curve analysis showed that this risk index had an area under the curve (AUC) of 0.783, with a power of 0.999, significance level of 0.05 and an overall accuracy of 79.0% (Figure 1).
Table 7 Predictive model of recurrent Clostridioides difficile infection.
Figure 1 ROC curve (receiver operating characteristic curve) of our model of independent risk factors for developing a recurrent CDI: faecal calprotectin level >185µg/mg, toxin B PCR cycle lower than 23, immunosuppression, female gender, age higher than 65 years, and creatinin levels higher than 1mg/dL (all p<0.05).
3.3 Community structure (diversity)
When studying the primary episode microbiome diversity of patients who went on to develop R-CDI and those who did not, we found significant differences in the inverse Simpson index (p=0.021), with lower values in patients with non-recurrent disease.
We found significant differences between those who presented any type of inflammatory bowel disease in the Shannon index, richness and evenness, with lower values than those of patients who did not present this condition (all p<0.05). Patients with a nasogastric tube during the month prior to the episode had lower values in the Shannon index, richness and evenness (all p<0.05).We found lower evenness values for patients who had taken probiotics in the month prior to the episode and those who had undergone colectomy or ileostomy and lower richness values for smokers and patients who had received antifungal treatment in the month prior to the episode.
We also studied the effects of antibiotics on the diversity of the microbiota and found that patients who received more than 3 antibiotics had less alpha diversity, less evenness (all p<0.05) and significant differences in beta diversity with respect to patients who received fewer than 3 antibiotics. The differences in alpha diversity and evenness remained significant in patients with recurrent disease compared with those who had non-recurrent disease.
In terms of beta diversity and of the variance of the intra-group samples, we found no significant differences between the recurrent and the non-recurrent group.
3.4 Community composition (relative abundance of taxa)
Regarding the relative abundance of the different taxonomic groups, we found that Bacteroidetes was the major phylum in patients with non-recurrent disease (40.18%), followed by Firmicutes (35.69%), whereas in those with recurrent disease, the major phylum was Firmicutes (38.26%), followed by Bacteroidetes (37.63%). Differences in relative abundance between the groups were not significant.
At the taxonomic family level, we found Bacteroidaceae to be the most abundant taxon in all patients (non-recurrent, 30.57%; recurrent, 28.02%), followed by Enterobacteriaceae (non-recurrent, 16.77%; recurrent, 13.75%) (Figure 2). When we analysed the taxonomic level of genus, we found that Fusobacterium increased in abundance in recurrent versus non-recurrent disease and that Collinsella, Senegalimassilia, Prevotella and Ruminococcus decreased in abundance in recurrent versus non-recurrent disease (all p<0.05) (Figure 3).
Figure 2 Heatmap of family relative abundance in each sample, divided in Non-recurrent patients (group Non-Rec; left) and recurrent patients (Rec; right).
Figure 3 Genus Log2 Fold Change represent differentially abundance genus between groups. Recurrent patients vs Non-recurrent patients.
Our analysis of the differences between patients with calprotectin levels >185µg/mg and those with levels <185µg/mg revealed that, as in the recurrent group, Fusobacterium increased and Senegalimassilia, Prevotella and Ruminococcus decreased. We also found other differences such as lower abundance of Lactobacillus, Lactococcus, Streptococcus, Blautia, Dorea, Bacteroides, Faecalicoccus, Clostridium XVIa and Parasutterella in patients with faecal calprotectin >185µg/mg than in those with lower values (all p<0.05) (Figure 4).
Figure 4 Genus Log2 Fold Change represent differentially abundance genus between the following groups: Fecal calprotectin >185μg/mg vs <185μg/mg.
We performed a multivariable association study between microbial communities and clinical metadata and found that the genera Senegalimassilia, Alistipes, Blautia and Lactococcus had a negative association with faecal calprotectin concentration and that the genera Bacteroides, Fusobacterium and Dialister had a positive association with faecal calprotectin concentration (all p<0.05) (Table 8).
Table 8 Association between microbial communities and calprotectin concentrations.
In terms of similarities between the OTUs of both groups, we found that they shared 1921 OTUs: 1119 unique OTUs in the recurrent group and 2241 unique OTUs in the non-recurrent group.
4 Discussion
In the present study, we profiled the microbiota of a large cohort of patients with CDI and found marked differences that could be useful in predicting R-CDI. We also established a significant association between elevated calprotectin values in patients who will subsequently develop R-CDI and built a risk index for R-CDI.
Several studies have characterised the microbiota in patients with CDI and R-CDI, although very few have attempted to establish relationships between gut microbiota and the likelihood of developing R-CDI (Khanna et al., 2016; Seekatz et al., 2016; Pakpour et al., 2017; Dawkins et al., 2022). These studies include a limited number of patients, and their results are conflicting.
With respect to diversity, we found significant differences in alpha diversity (inverse Simpson index) between patients who later developed R-CDI and those who did not. This was also observed in a smaller study by Pakpour et al. (Pakpour et al., 2017). When studying beta diversity, we did not observe any significant differences between the recurrent and non-recurrent groups, consistent with findings published elsewhere, except for those of Pakpour et al. who found significant differences in beta diversity between these groups (Khanna et al., 2016; Seekatz et al., 2016; Pakpour et al., 2017; Dawkins et al., 2022).
With respect to changes in genus abundance, we observed significant differences in genera such as Fusobacterium, which is more abundant in recurrent than non-recurrent disease, and in Collinsella, Senegalimassilia, Prevotella and Ruminococcus, with lower abundance in recurrent than in non-recurrent disease. Very few data have been reported on taxa abundance in patients with primary CDI who later develop R-CDI, and the available data are conflicting (Khanna et al., 2016; Seekatz et al., 2016; Pakpour et al., 2017; Dawkins et al., 2022).
The genus Fusobacterium, which we observed to have higher abundance in patients who will further develop R-CDI, is considered an opportunistic pathogen associated with a wide range of human conditions, including inflammatory bowel disease, colorectal cancer, preterm birth and intestinal inflammation (Strauss et al., 2011; Amitay et al., 2017; Engevik et al., 2021). The genera that we found in lower abundance in patients with recurrent disease, such as Collinsella, Senegalimassilia, Prevotella and Ruminococcus, were previously associated with healthy individuals, had anti-inflammatory properties and produced metabolites that are very important for the preservation of the intestinal barrier (Ze et al., 2012; Ko et al., 2017; Adamberg et al., 2018; Yeoh et al., 2022).
The devalences of these genera could play a role in maintaining intestinal inflammation and thus providing a favourable environment for new R-CDI, although this has not been demonstrated.
These microbiota findings may relate to the results we had obtained for calprotectin, with higher levels in recurrent disease than in non-recurrent disease, as calprotectin is a good biomarker of intestinal inflammation. We also found the same response for some of the above-mentioned genera in patients with high calprotectin levels than in those with low calprotectin levels. In this sense, at diagnosis, patients who are likely to develop R-CDI have higher levels of calprotectin, together with a higher abundance of Fusobacterium and lower abundance of Senegalimassilia, Prevotella and Ruminococcus. To the best of our knowledge, this is the first study to report an association between calprotectin levels and microbiota abundance alterations (in CDI).
However, although it is known that faecal calprotectin reaches the gut via migration of neutrophils into gastrointestinal tissues due to inflammatory processes, the exact mechanism by which this happens, and the genera or species of microbes involved in this process, are not known (Pathirana et al., 2018).
In the literature, some studies use calprotectin levels to distinguish true episodes of CDI from colonisation by C. difficile (Popiel et al., 2015) or to classify the severity of the CDI episode. We obtained statistically significantly higher levels of faecal calprotectin in severe episodes than in mild episodes, consistent with previous studies, which reported significant results between calprotectin levels and the severity of the CDI episode. (Barbut et al., 2017; Kim et al., 2017; Han et al., 2020; Suarez-Carantoña et al., 2021). However, few studies have investigated the relationship between calprotectin levels and risk of developing R-CDI: those that did showed no significant association between R-CDI and calprotectin levels, and most of them included a low number of patients studied or only included a specific subpopulation such as children or cancer patients (Swale et al., 2014; Peretz et al., 2016; Nicholson et al., 2017; He et al., 2018). Our results for calprotectin reveal a significant association between elevated calprotectin values in patients who will subsequently develop R-CDI, possibly because we analysed a large cohort of patients.
We propose an early prediction model for R-CDI based on clinical and analytical data such as age, sex, immunosuppression, creatinine level, calprotectin level and C. difficile PCR toxin B gene cycle, which can be assessed using commercially available PCR methods found in many microbiology laboratories. Our R-CDI prediction model included variables already known to be risk factors for R-CDI or poor outcome of CDI, such as advanced age, female sex, creatinine levels >1mg/dL, C. difficile PCR toxin B gene cycle threshold <23, immunosuppression and faecal calprotectin levels (Hu et al., 2009; Eyre et al., 2012; Lupse et al., 2013; Miller et al., 2013; Reigadas et al., 2016; Origüen et al., 2019; Alrahmany et al., 2021).
Hence, the data on which the model is based are easy to obtain at the time of diagnosis of the primary CDI episode, with a reasonable AUC (0.783). Although several prediction models have been developed for R-CDI (Eyre et al., 2012; D’Agostino et al., 2014; LaBarbera et al., 2015; Escobar et al., 2017; Cobo et al., 2018; Ruzicka et al., 2022), none have been widely implemented in clinical practice. External validations of prediction tools have revealed disappointing results, probably owing to the low quality of most studies and the small effects of the proposed prognostic factors (van Rossen et al., 2022).
Most of these predictive R-CDI models yielded much lower AUC values than ours, including those of Ruzicka et al. (AUC 0.65-0.63), Cobo et al. (AUC 0.72), Zilberberg et al. (AUC 0.643), Escobar et al. (AUC 0.591-0.605), D’Agostino et al. (AUC 0.64) and Larrainzar-Coghen et al. (AUC 0.66). Of these models, only that of Cobo et al. incorporated laboratory parameters related to C. difficile (D’Agostino et al., 2014; Larrainzar-Coghen et al., 2016; Zilberberg et al., 2016; Escobar et al., 2017; Cobo et al., 2018; Ruzicka et al., 2022).Origüen et al. obtained a predictive model for R-CDI with an AUC very similar to ours, ie, 0.785. Their model also included the PCR cycles of the C. difficile toxin (as did ours), although when they included the result of toxin detection by EIA, their AUC dropped to 0.775 (Origüen et al., 2019). We found only 2 models with higher AUC values than ours, namely, that of Hu et al. (AUC 0.80 in the validation cohort, 0.62 in the derivation cohort), which includes the detection of C. difficile antitoxin A IgG, and that of LaBarbera et al. (AUC 0.83), which does not include any laboratory parameters (Hu et al., 2009; LaBarbera et al., 2015). However, given that the model of Hu et al. is based on obtaining antitoxin IgA levels at day 12 of the CDI diagnosis, it cannot be used to guide treatment at the beginning of the episode. The model of LaBarbera et al. was complex, including 25 different variables with an overall accuracy of 66.1%, whereas ours was 79%. Having a simple and good R-CDI prediction model could help to guide early treatment of R-CDI.
Our study and our prediction model are limited by their single-centre design; therefore, our results should be validated in multicentre studies. On the other hand, we recruited a large number of patients, making ours the largest cohort to date in which microbiota in CDI and risk of recurrence are analysed. Our results can therefore be considered robust.
In conclusion, abundance of various bacterial genera and faecal calprotectin levels could be used as biomarkers to help identify patients who will develop R-CDI from those who will not. We also propose the use of our simple R-CDI risk index, which includes readily available data and rapid laboratory tests. The use of these early markers of R-CDI can guide management and treatment of the initial CDI episode, thus optimizing the use of resources, especially for patients who are at increased risk of R-CDI. Further research is warranted.
HGUGM Microbiome Group
Carmen Moreno, Mara Perellada, Celso Arando, Lorena Cussó, Manuel Desco, Javier Vaquero, Marta Fernández, Rafael Correa, Darío García de Viedma, Ana I. Fernández, Nuria López, Silvia Vázquez-Cuesta, Elena Reigadas, Javier Bermejo, Francisco Fernández-Avilés.
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ebi.ac.uk/ena, PRJEB57947.
Ethics statement
The studies involving human participants were reviewed and approved by Ethics Committee of Hospital General Universitario Gregorio Marañón in Madrid (number MICRO.HGUGM.2016-029). The patients/participants provided their written informed consent to participate in this study.
Author contributions
ER and EB designed the study. SV-C collected data and samples. SV-C and NG performed the data analysis. SV-C, ER, EB, MO, MK, LA, MM and PM contributed to data interpretation. SV-C wrote the first draft of the manuscript. SV-C, ER, EB, MO, MK, LA, MM, JB, FD, PM and AF contributed to the intellectual content and approved the final draft. SV-C, ER and EB had access to and verified the underlying study data. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. All authors contributed to the article and approved the submitted version.
Funding
This study has been funded by “Instituto de Salud Carlos III” (ISCIII) through the projects PI16/00490, PI20/01381, FI21/00310, PIE16/00055 and co-funded by the European Union.
Acknowledgments
We thank Thomas O’Boyle for his help in the preparation of the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2023.1237500/full#supplementary-material
References
Adamberg, K., Adamberg, S., Ernits, K., Larionova, A., Voor, T., Jaagura, M., et al. (2018). Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans. Anaerobe 52, 100–110. doi: 10.1016/j.anaerobe.2018.06.009
Alrahmany, D., Ereshefsky, B. J., El Nekidy, W. S., Harb, G., Pontiggia, L., Ghazi, I. M. (2021). Risk factors for recurrence of Clostridioides difficile in hospitalized patients. J. Infect. Public Health 14 (11), 1642–1649. doi: 10.1016/j.jiph.2021.09.016
Amitay, E. L., Werner, S., Vital, M., Pieper, D. H., Höfler, D., Gierse, I. J., et al. (2017). Fusobacterium and colorectal cancer: causal factor or passenger? Results from a large colorectal cancer screening study. Carcinogenesis 38 (8), 781–788. doi: 10.1093/carcin/bgx053
Barbut, F., Gouot, C., Lapidus, N., Suzon, L., Syed-Zaidi, R., Lalande, V., et al. (2017). Faecal lactoferrin and calprotectin in patients with Clostridium difficile infection: a case-control study. Eur. J. Clin. Microbiol. Infect. Dis. 36 (12), 2423–2430. doi: 10.1007/s10096-017-3080-y
Barbut, F., Richard, A., Hamadi, K., Chomette, V., Burghoffer, B., Petit, J. C. (2000). Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J. Clin. Microbiol. 38 (6), 2386–2388. doi: 10.1128/jcm.38.6.2386-2388.2000
Buffie, C. G., Jarchum, I., Equinda, M., Lipuma, L., Gobourne, A., Viale, A., et al. (2012). Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect. Immun. 80 (1), 62–73. doi: 10.1128/iai.05496-11
Charlson, M. E., Pompei, P., Ales, K. L., MacKenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40 (5), 373–383. doi: 10.1016/0021-9681(87)90171-8
Cobo, J., Merino, E., Martínez, C., Cózar-Llistó, A., Shaw, E., Marrodán, T., et al. (2018). Prediction of recurrent Clostridium difficile infection at the bedside: the GEIH-CDI score. Int. J. Antimicrob. Agents 51 (3), 393–398. doi: 10.1016/j.ijantimicag.2017.09.010
D’Agostino, R. B., Collins, S. H., Pencina, K. M., Kean, Y., Gorbach, S. (2014). Risk estimation for recurrent Clostridium difficile infection based on clinical factors. Clin. Infect. Dis. 58 (10), 1386–1393. doi: 10.1093/cid/ciu107
Dawkins, J. J., Allegretti, J. R., Gibson, T. E., McClure, E., Delaney, M., Bry, L., et al. (2022). Gut metabolites predict Clostridioides difficile recurrence. Microbiome 10 (1), 87. doi: 10.1186/s40168-022-01284-1
Dubberke, E. R., Puckett, J. T., Obi, E. N., Kamal-Bahl, S., Desai, K., Stuart, B., et al. (2022). Impact of updated clinical practice guidelines on outpatient treatment for Clostridioides difficile infection and associated clinical outcomes. Open Forum Infect. Dis. 9 (10), ofac435. doi: 10.1093/ofid/ofac435
Edgeworth, J., Gorman, M., Bennett, R., Freemont, P., Hogg, N. (1991). Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J. Biol. Chem. 266 (12), 7706–7713. doi: 10.1016/S0021-9258(20)89506-4
Engevik, M. A., Danhof, H. A., Ruan, W., Engevik, A. C., Chang-Graham, A. L., Engevik, K. A., et al. (2021). Fusobacterium nucleatum secretes outer membrane vesicles and promotes intestinal inflammation. mBio 12 (2). doi: 10.1128/mBio.02706-20
Escobar, G. J., Baker, J. M., Kipnis, P., Greene, J. D., Mast, T. C., Gupta, S. B., et al. (2017). Prediction of recurrent Clostridium difficile infection using comprehensive electronic medical records in an integrated healthcare delivery system. Infect. Control Hosp Epidemiol. 38 (10), 1196–1203. doi: 10.1017/ice.2017.176
Escudero-Sánchez, R., Ruíz-Ruizgómez, M., Fernández-Fradejas, J., García Fernández, S., Olmedo Samperio, M., Cano Yuste, A., et al. (2020). Real-world experience with bezlotoxumab for prevention of recurrence of Clostridioides difficile infection. J. Clin. Med. 10 (1). doi: 10.3390/jcm10010002
Eyre, D. W., Walker, A. S., Wyllie, D., Dingle, K. E., Griffiths, D., Finney, J., et al. (2012). Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin. Infect. Dis. 55 (Suppl 2), S77–S87. doi: 10.1093/cid/cis356
Feuerstadt, P., Louie, T. J., Lashner, B., Wang, E. E. L., Diao, L., Bryant, J. A., et al. (2022). SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl. J. Med. 386 (3), 220–229. doi: 10.1056/NEJMoa2106516
Feuerstadt, P., Stong, L., Dahdal, D. N., Sacks, N., Lang, K., Nelson, W. W. (2020). Healthcare resource utilization and direct medical costs associated with index and recurrent Clostridioides difficile infection: a real-world data analysis. J. Med. Econ 23 (6), 603–609. doi: 10.1080/13696998.2020.1724117
Galgut, B. J., Lemberg, D. A., Day, A. S., Leach, S. T. (2018). The value of fecal markers in predicting relapse in inflammatory bowel diseases. Front. Pediatr. 5. doi: 10.3389/fped.2017.00292
Gonzalez, M. D., Wilen, C. B., Burnham, C. A. (2015). Markers of intestinal inflammation for the diagnosis of infectious gastroenteritis. Clin. Lab. Med. 35 (2), 333–344. doi: 10.1016/j.cll.2015.02.001
Han, S. H., Yi, J., Kim, J. H., Moon, A. H. (2020). Investigation of intestinal microbiota and fecal calprotectin in non-toxigenic and toxigenic Clostridioides difficile colonization and infection. Microorganisms 8 (6). doi: 10.3390/microorganisms8060882
He, T., Kaplan, S. E., Gomez, L. A., Lu, X., Ramanathan, L. V., Kamboj, M., et al. (2018). Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection. Eur. J. Clin. Microbiol. Infect. Dis. 37 (12), 2341–2346. doi: 10.1007/s10096-018-3381-9
Heimann, S. M., Cruz Aguilar, M. R., Mellinghof, S., Vehreschild, M. (2018). Economic burden and cost-effective management of Clostridium difficile infections. Med. Mal Infect. 48 (1), 23–29. doi: 10.1016/j.medmal.2017.10.010
Hu, M. Y., Katchar, K., Kyne, L., Maroo, S., Tummala, S., Dreisbach, V., et al. (2009). Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 136 (4), 1206–1214. doi: 10.1053/j.gastro.2008.12.038
Huang, Y. Q., Gou, R., Diao, Y. S., Yin, Q. H., Fan, W. X., Liang, Y. P., et al. (2014). Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy. J. Zhejiang Univ Sci. B 15 (1), 58–66. doi: 10.1631/jzus.B1300109
Jangi, S., Lamont, J. T. (2010). Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. J. Pediatr. Gastroenterol. Nutr. 51 (1), 2–7. doi: 10.1097/MPG.0b013e3181d29767
Johnson, T. M., Molina, K. C., Howard, A. H., Schwarz, K., Allen, L., Huang, M., et al. (2022). Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence. Clin. Infect. Dis. 74 (9), 1572–1578. doi: 10.1093/cid/ciab674
Kates, A. E., Gaulke, I., De Wolfe, T., Zimbric, M., Haight, K., Watson, L., et al. (2020). Fecal microbiota transplantation for patients on antibiotic treatment with C. difficile infection history (GRAFT): Study protocol for a phase II, randomized, double-blind, placebo-controlled trial to prevent recurrent C. difficile infections. Contemp Clin. Trials Commun. 18, 100576. doi: 10.1016/j.conctc.2020.100576
Khanna, S., Montassier, E., Schmidt, B., Patel, R., Knights, D., Pardi, D. S., et al. (2016). Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection. Aliment Pharmacol. Ther. 44 (7), 715–727. doi: 10.1111/apt.13750
Kim, J., Kim, H., Oh, H. J., Kim, H. S., Hwang, Y. J., Yong, D., et al. (2017). Fecal calprotectin level reflects the severity of Clostridium difficile infection. Ann. Lab. Med. 37 (1), 53–57. doi: 10.3343/alm.2017.37.1.53
Ko, W. K., Lee, S. H., Kim, S. J., Jo, M. J., Kumar, H., Han, I. B., et al. (2017). Anti-inflammatory effects of ursodeoxycholic acid by lipopolysaccharide-stimulated inflammatory responses in RAW 264.7 macrophages. PloS One 12 (6), e0180673. doi: 10.1371/journal.pone.0180673
Kumar, A., Steinkasserer, A., Berchtold, S. (2003). Interleukin-10 influences the expression of MRP8 and MRP14 in human dendritic cells. Int. Arch. Allergy Immunol. 132 (1), 40–47. doi: 10.1159/000073263
LaBarbera, F. D., Nikiforov, I., Parvathenani, A., Pramil, V., Gorrepati, S. (2015). A prediction model for Clostridium difficile recurrence. J. Community Hosp. Internal Med. Perspect. 5 (1), 26033. doi: 10.3402/jchimp.v5.26033
Larrainzar-Coghen, T., Rodriguez-Pardo, D., Puig-Asensio, M., Rodríguez, V., Ferrer, C., Bartolomé, R., et al. (2016). First recurrence of Clostridium difficile infection: clinical relevance, risk factors, and prognosis. Eur. J. Clin. Microbiol. Infect. Dis. 35 (3), 371–378. doi: 10.1007/s10096-015-2549-9
Lasson, A., Stotzer, P. O., Öhman, L., Isaksson, S., Sapnara, M., Strid, H. (2015). The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J. Crohns Colitis 9 (1), 26–32. doi: 10.1016/j.crohns.2014.06.002
Leffler, D. A., Lamont, J. T. (2015). Clostridium difficile infection. N Engl. J. Med. 372 (16), 1539–1548. doi: 10.1056/NEJMra1403772
Lehmann, F. S., Burri, E., Beglinger, C. (2015). The role and utility of faecal markers in inflammatory bowel disease. Therap Adv. Gastroenterol. 8 (1), 23–36. doi: 10.1177/1756283x14553384
Lupse, M., Flonta, M., Cioara, A., Filipescu, I., Todor, N. (2013). Predictors of first recurrence in Clostridium difficile-associated disease. A study of 306 patients hospitalized in a ROmanian tertiary referral center. J. Gastrointestin Liver Dis. 22 (4), 397–403.
Mallick, H., Rahnavard, A., McIver, L. J., Ma, S., Zhang, Y., Nguyen, L. H., et al. (2021). Multivariable association discovery in population-scale meta-omics studies. PloS Comput. Biol. 17 (11), e1009442. doi: 10.1371/journal.pcbi.1009442
McCabe, W. R., Jackson, G. G. (1962). Gram-negative bacteremia: I. Etiology and ecology. Arch. Internal Med. 110 (6), 847–855. doi: 10.1001/archinte.1962.03620240029006
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., et al. (2018). Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA). Clin. Infect. Dis. 66 (7), 987–994. doi: 10.1093/cid/ciy149
Miller, M. A., Louie, T., Mullane, K., Weiss, K., Lentnek, A., Golan, Y., et al. (2013). Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect. Dis. 13, 148. doi: 10.1186/1471-2334-13-148
Mulder, M., Radjabzadeh, D., Kiefte-de Jong, J. C., Uitterlinden, A. G., Kraaij, R., Stricker, B. H., et al. (2020). Long-term effects of antimicrobial drugs on the composition of the human gut microbiota. Gut Microbes 12 (1), 1795492. doi: 10.1080/19490976.2020.1791677
Nicholson, M. R., Crews, J. D., Starke, J. R., Jiang, Z. D., DuPont, H., Edwards, K. (2017). Recurrent Clostridium difficile infection in children: patient risk factors and markers of intestinal inflammation. Pediatr. Infect. Dis. J. 36 (4), 379–383. doi: 10.1097/inf.0000000000001450
Odink, K., Cerletti, N., Brüggen, J., Clerc, R. G., Tarcsay, L., Zwadlo, G., et al. (1987). Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 330 (6143), 80–82. doi: 10.1038/330080a0
Origüen, J., Orellana, M., Fernández-Ruiz, M., Corbella, L., San Juan, R., Ruiz-Ruigómez, M., et al. (2019). Toxin B PCR amplification cycle threshold adds little to clinical variables for predicting outcomes in Clostridium difficile infection: a retrospective cohort study. J. Clin. Microbiol. 57 (2). doi: 10.1128/jcm.01125-18
Pakpour, S., Bhanvadia, A., Zhu, R., Amarnani, A., Gibbons, S. M., Gurry, T., et al. (2017). Identifying predictive features of Clostridium difficile infection recurrence before, during, and after primary antibiotic treatment. Microbiome 5 (1), 148. doi: 10.1186/s40168-017-0368-1
Pathirana, W. G. W., Chubb, S. P., Gillett, M. J., Vasikaran, S. D. (2018). Faecal calprotectin. Clin. Biochem. Rev. 39 (3), 77–90.
Peretz, A., Tkhawkho, L., Pastukh, N., Brodsky, D., Halevi, C. N., Nitzan, O. (2016). Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection. BMC Infect. Dis. 16, 309. doi: 10.1186/s12879-016-1618-8
Popiel, K. Y., Gheorghe, R., Eastmond, J., Miller, M. A. (2015). Usefulness of adjunctive fecal calprotectin and serum procalcitonin in individuals positive for Clostridium difficile toxin gene by PCR assay. J. Clin. Microbiol. 53 (11), 3667–3669. doi: 10.1128/jcm.02230-15
R Core Team (2021). A Language and Environment for Statistical Computing (Vienna, Austria: R Foundation for Statistical Computing). Available online: https://www.R-project.org/.
Reigadas, E., Alcalá, L., Valerio, M., Marín, M., Martin, A., Bouza, E. (2016). Toxin B PCR cycle threshold as a predictor of poor outcome of Clostridium difficile infection: a derivation and validation cohort study. J. Antimicrob. Chemother. 71 (5), 1380–1385. doi: 10.1093/jac/dkv497
Reigadas Ramirez, E., Bouza, E. S. (2018). Economic burden of Clostridium difficile infection in European countries. Adv. Exp. Med. Biol. 1050, 1–12. doi: 10.1007/978-3-319-72799-8_1
Rupnik, M., Wilcox, M. H., Gerding, D. N. (2009). Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 7 (7), 526–536. doi: 10.1038/nrmicro2164
Ruzicka, D., Kondo, T., Fujimoto, G., Craig, A. P., Kim, S. W., Mikamo, H. (2022). Development of a clinical prediction model for recurrence and mortality outcomes after Clostridioides difficile infection using a machine learning approach. Anaerobe 77, 102628. doi: 10.1016/j.anaerobe.2022.102628
Seekatz, A. M., Rao, K., Santhosh, K., Young, V. B. (2016). Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection. Genome Med. 8 (1), 47. doi: 10.1186/s13073-016-0298-8
Smits, W. K., Lyras, D., Lacy, D. B., Wilcox, M. H., Kuijper, E. J. (2016). Clostridium difficile infection. Nat. Rev. Dis. Primers 2, 16020. doi: 10.1038/nrdp.2016.20
Stathaki, M. I., Koukouraki, S. I., Karkavitsas, N. S., Koutroubakis, I. E. (2009). Role of scintigraphy in inflammatory bowel disease. World J. Gastroenterol. 15 (22), 2693–2700. doi: 10.3748/wjg.15.2693
Strauss, J., Kaplan, G. G., Beck, P. L., Rioux, K., Panaccione, R., Devinney, R., et al. (2011). Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflammation Bowel Dis. 17 (9), 1971–1978. doi: 10.1002/ibd.21606
Suarez-Carantoña, C., Rodriguez-Torres, A., Viteri-Noel, A., Pintado, V., Garcia-Fernandez, S., Mora-Pimentel, D., et al. (2021). Usefulness of fecal calprotectin in the management of patients with toxigenic Clostridioides difficile. J. Clin. Med. 10 (8). doi: 10.3390/jcm10081627
Swale, A., Miyajima, F., Roberts, P., Hall, A., Little, M., Beadsworth, M. B., et al. (2014). Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study. PloS One 9 (8), e106118. doi: 10.1371/journal.pone.0106118
Tashiro, S., Mihara, T., Sasaki, M., Shimamura, C., Shimamura, R., Suzuki, S., et al. (2022). Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials. J. Infect. Chemother. 28 (11), 1536–1545. doi: 10.1016/j.jiac.2022.08.008
Theriot, C. M., Bowman, A. A., Young, V. B. (2016). Antibiotic-induced alterations of the gut microbiota alter secondary bile acid production and allow for Clostridium difficile spore germination and outgrowth in the large intestine. mSphere 1 (1). doi: 10.1128/mSphere.00045-15
Tougas, S. R., Lodha, N., Vandermeer, B., Lorenzetti, D. L., Tarr, P. I., Tarr, G. A. M., et al. (2021). Prevalence of detection of Clostridioides difficile among asymptomatic children: A systematic review and meta-analysis. JAMA Pediatr. 175 (10), e212328. doi: 10.1001/jamapediatrics.2021.2328
van Prehn, J., Reigadas, E., Vogelzang, E. H., Bouza, E., Hristea, A., Guery, B., et al. (2021). European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin. Microbiol. Infection 27, S1–S21. doi: 10.1016/j.cmi.2021.09.038
van Rossen, T. M., Ooijevaar, R. E., Vandenbroucke-Grauls, C. M. J. E., Dekkers, O. M., Kuijper, E. J., Keller, J. J., et al. (2022). Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review. Clin. Microbiol. Infection 28 (3), 321–331. doi: 10.1016/j.cmi.2021.09.026
Whittaker, R. J., Willis, K. J., Field, R. (2001). Scale and species richness: towards a general, hierarchical theory of species diversity. J. Biogeography 28 (4), 453–470. doi: 10.1046/j.1365-2699.2001.00563.x
WHO (2021). Guidelines for ATC classification and DDD assignment 2021 (Oslo, Norway: World Health Organization). Available at: www.whocc.no.
Wingen-Heimann, S. M., Davies, K., Viprey, V. F., Davis, G., Wilcox, M. H., Vehreschild, M., et al. (2022). Clostridioides difficile infection (CDI): A pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI). Clin. Microbiol. Infect. 29, 651.e1–651.e8. doi: 10.1016/j.cmi.2022.12.019
Xu, K., Geczy, C. L. (2000). IFN-gamma and TNF regulate macrophage expression of the chemotactic S100 protein S100A8. J. Immunol. 164 (9), 4916–4923. doi: 10.4049/jimmunol.164.9.4916
Yeoh, Y. K., Sun, Y., Ip, L. Y. T., Wang, L., Chan, F. K. L., Miao, Y., et al. (2022). Prevotella species in the human gut is primarily comprised of Prevotella copri, Prevotella stercorea and related lineages. Sci. Rep. 12 (1), 9055. doi: 10.1038/s41598-022-12721-4
Yurkovich, M., Avina-Zubieta, J. A., Thomas, J., Gorenchtein, M., Lacaille, D. (2015). A systematic review identifies valid comorbidity indices derived from administrative health data. J. Clin. Epidemiol. 68 (1), 3–14. doi: 10.1016/j.jclinepi.2014.09.010
Ze, X., Duncan, S. H., Louis, P., Flint, H. J. (2012). Ruminococcus bromii is a keystone species for the degradation of resistant starch in the human colon. ISME J. 6 (8), 1535–1543. doi: 10.1038/ismej.2012.4
Keywords: calprotectin, biomarkers, C. difficile, microbiome, R-CDI, 16S rRNA, prediction model
Citation: Vázquez-Cuesta S, Lozano García N, Fernández AI, Olmedo M, Kestler M, Alcalá L, Marín M, Bermejo J, Díaz FF-A, Muñoz P, Bouza E and Reigadas E (2023) Microbiome profile and calprotectin levels as markers of risk of recurrent Clostridioides difficile infection. Front. Cell. Infect. Microbiol. 13:1237500. doi: 10.3389/fcimb.2023.1237500
Received: 09 June 2023; Accepted: 23 August 2023;
Published: 13 September 2023.
Edited by:
Piyush Baindara, University of Missouri, United StatesReviewed by:
Prajita Paul, Johns Hopkins University, United StatesNeha Thakre, University of California, San Diego, United States
Maryam Meskini, Pasteur Institute of Iran, Iran
Copyright © 2023 Vázquez-Cuesta, Lozano García, Fernández, Olmedo, Kestler, Alcalá, Marín, Bermejo, Díaz, Muñoz, Bouza and Reigadas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Silvia Vázquez-Cuesta, c2lsdmlhdmF6cXVlei5sYWJAZ21haWwuY29t